The reversal of inhibitors in congenital hemophilia

Pharmacotherapy

Volumn 33, Issue 2, 2013, Pages 157-164

  Defrates, Sean R ^a   McDonagh, Kevin T ^b   Adams, Val R ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alloantibodies; Hemophilia; Immune tolerance; Inhibitors; Rituximab

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB;

BLEEDING; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFECTION; MEDICAID; MEDICARE; MORBIDITY; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES;

EID: 84875426784     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1173     Document Type: Review

References (44)

1. Mannucci PM, Tuddenham EGD. The hemophilias- from royal genes to gene therapy. N Engl J Med 2001;344 (23):1773-9.
2. White GC II, Frits Rosendaal LM, Aledort JM, et al. Definitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee on the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85: 560.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44.
4. Kruse-Jarres R. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A. Hematology Am Soc Hematol Educ Program 2011;2011:407-12.
5. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2010; 72(4):553-62.
6. Scandella DH. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost 2000;26 (2):137-42.
7. Spiegel PC. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001;98 (1):13-9.
8. Reipert BM, van den Helden PMW, Schwarz H-P, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007;136(1):12-25.
9. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009;7(9):1446-56.
10. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia. 2006;12(suppl 6):74-9; discussion 79-80.
11. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102 (7):2358-63.
12. Centers for Medicare & Medicaid Services. ASP drug pricing files. 2011. Available from http://www1b.cms.gov/Medicare/Medicare-Fee-for-Service- Part-B-Drugs/McrPartBDrugAvgSalesPrice/01a18-2011ASPFiles.html. Accessed September 21, 2011.
13. Shord SS, Lindley CM. Coagulation products and their uses. Am J Health Syst Pharm 2000;57(15):1403-17.
14. Astermark J, Morado M, Rocino A, et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006;12(4): 363-71.
15. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007;13(suppl 1): 1-22.
16. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol.' Vox Sang 1996;70(suppl 1):30-5.
17. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988;318(15):947-50.
18. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmo protocol update. Haematologica 2000;85(Suppl 10):48-50; discussion 50-41.
19. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86(3):983-8.
20. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002;87(1):52-7.
21. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003;29(1):69-76.
22. Kroner BL. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang 1999;77(Suppl 1):33-7.
23. Dimichele DM, Hay CR. The International Immune Tolerance Study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006;4(10):2271-3.
24. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119(6):1335-44.
25. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003;88(6):EREP03.
26. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 2010;104(5):931-40.
27. Cross DC, Van Der Berg HM. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 2007;13(1):111-4.
28. Hruby MA, Schulman I. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia. Blood 1973;42(6):919-23.
29. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976;16(5):369-82.
30. Klarmann D, Martinez Saguer I, Funk MB, et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008;14(1): 44-9.
31. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48(6):1484-92.
32. Reff M, Carner K, Chambers KS, et al. Depletion of B Cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45.
33. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 pt 1):859-66.
34. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46(10): 2673-7.
35. Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology 2005;44 (suppl 2):ii13-7.
36. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007;63(1):47-52.
37. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141(2):149-69.
38. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haemotol 2004;125: 366-8.
39. Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008;30(1):93-5.
40. Carcao M, St Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006;12(1):7-18.
41. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977- 99. J Thromb Haemost 2004;2(7):1047-54.
42. Dunkley S, Kershaw G, Young G, et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia 2006;12(6):663-7.
43. Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008;14(5):903-12.
44. Collins PW, Mathias M, Hanley J, et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009;7(5):787-94.